Shire’s stalker raises its offer

US pharmaceuticals group AbbVie has made a fourth attempt to bag London-listed Shire Pharmaceuticals.

US pharmaceuticals group AbbVie has made a fourth attempt to bag London-listed Shire Pharmaceuticals. Its latest unsolicited bid is worth £30bn, or just over £51 a share an 11% improvement on the previous bid.

AbbVie urged Shire's shareholders to persuade the board to enter talks. AbbVie is best known for Humira, a rheumatoid arthritis drug. Shire specialises in drugs for attention deficit hyperactivity disorder.

What the commentators said

Back then, it was easy to point out that Pfizer was keen to take over Astra largely for tax purposes: it would keep its bills down by moving its domicile to the UK.

But this situation is different. While so-called tax inversion plays a part in AbbVie's motives, "Shire's role as a UK pharmaceutical powerhouse is undermined" by its own tax exile in Ireland, said Brummer; it has been based there for eight years. If AbbVie takes it over, Shire will actually come home.

In any case, Shire has never been a "research and development champion" in the Astra or GlaxoSmithKline mould.It has expanded largely by acquisition.

Plenty of shareholders will be happy with the offer, said Nils Pratley in The Guardian the shares traded at £35 before the bid surfaced. But AbbVie can pay more. Bank of America reckons it could stretch to £59 and still break even.

Shire's own growth target will also bolster its defences, said Navid Malik of Cenkos. It plans to double revenue by 2020, achievable given its "track record of building value". "Its value as a stand-alone company is very compelling."

Recommended

The British equity market is shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
Why China appeals to good investors
China stockmarkets

Why China appeals to good investors

China is one of the few places left to good investors hoping to make a decent return, says Merryn Somerset Webb.
14 Sep 2020
Mega-cap tech stocks: a very crowded trade
Tech stocks

Mega-cap tech stocks: a very crowded trade

It’s a dangerous time for markets when investors can no longer afford to go against the consensus
14 Sep 2020

Most Popular

Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
James Ferguson: How bad data is driving fear of a second wave of Covid-19
UK Economy

James Ferguson: How bad data is driving fear of a second wave of Covid-19

Merryn and John talk to MoneyWeek regular James Ferguson about the rise in infections in coronavirus and what the data is really telling us.
17 Sep 2020